Market Overview
The global mRNA vaccines and therapeutics market size is expected to reach USD 253.83 billion by 2034, exhibiting a CAGR of 16.7% 2025–2034.
The mRNA vaccines and therapeutics market has experienced significant growth in recent years, catalyzed by the global COVID-19 pandemic. Messenger RNA (mRNA) technology, which had been under development for decades, gained worldwide attention due to its success in developing COVID-19 vaccines. Unlike traditional vaccines, mRNA vaccines work by instructing cells to produce proteins that trigger an immune response. This technology is seen as a breakthrough for not just vaccines but also a wide range of therapeutic applications, including cancer treatments, genetic disorders, and infectious diseases.
The market growth is driven by several factors, including increased funding in mRNA research, rising acceptance of mRNA-based treatments, and significant advancements in clinical trials.
𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
List of Key Companies in mRNA Vaccines and Therapeutics Market
- Pfizer Inc.
- Moderna, Inc.
- BioNTech SE
- GlaxoSmithKline
- Daiichi Sankyo
- BioNTech SE
- CureVac N.V.
- AstraZeneca
- Ethris
Market’s Growth Drivers
- COVID-19 Vaccine Success: The success of the mRNA-based COVID-19 vaccines developed by Pfizer-BioNTech and Moderna has been a major growth driver. These vaccines demonstrated both efficacy and safety, leading to the widespread acceptance of mRNA technology in the field of immunization. The fast-track development and approval of COVID-19 vaccines have paved the way for mRNA technologies to be utilized in other vaccine development and therapeutics.
- Increased Investment in mRNA Research: The rapid advancement of mRNA technology is fueled by substantial investments from governments, pharmaceutical companies, and biotech firms. The ongoing funding and research initiatives are expected to further develop mRNA vaccines and therapeutics for other infectious diseases, such as influenza, Zika, and respiratory syncytial virus (RSV).
- Expanding Therapeutic Applications: While mRNA vaccines have gained prominence, the technology’s potential in therapeutics is also expanding. Researchers are exploring the use of mRNA in gene therapies for genetic diseases, cancer immunotherapies, and treatments for cardiovascular diseases. The versatility of mRNA technology to target various diseases is a significant factor in the market’s growth.
- Advances in Delivery Systems: A key challenge for mRNA therapeutics has been the efficient delivery of mRNA into cells. Advances in lipid nanoparticles (LNPs) and other delivery systems have improved the stability, efficiency, and targeted delivery of mRNA, increasing the potential for clinical applications.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:
The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.
mRNA Vaccines and Therapeutics Market, Type Outlook (Revenue – USD Billion, 2020-2034)
- Self-Amplifying mRNA-based Vaccines
- Conventional Non-Amplifying mRNA-Based Vaccines
mRNA Vaccines and Therapeutics Market, Application Outlook (Revenue – USD Billion, 2020-2034)
- Cancer
- Infectious Diseases
- Autoimmune Diseases
- Others
mRNA Vaccines and Therapeutics Market, Treatment Type Outlook (Revenue – USD Billion, 2020-2034)
- Monoclonal Antibody
- Gene Therapy
- Cell Therapy
- Other
mRNA Vaccines and Therapeutics Market, End User Outlook (Revenue – USD Billion, 2020-2034)
- Research Laboratories and Organizations
- Hospitals
- Clinics
- Others
Key Trends
- Customization of mRNA Vaccines: Personalized medicine is a growing trend, and mRNA vaccines are seen as a key player in this field. Tailored vaccines designed for individuals based on their genetic profile or specific cancer mutations are becoming more feasible. Companies are focusing on the development of individualized mRNA-based cancer vaccines, which could provide more effective treatments for patients.
- Combination Therapies: Another trend is the development of combination therapies that use mRNA-based vaccines or treatments alongside other treatment modalities like checkpoint inhibitors or monoclonal antibodies. Combining therapies could enhance the immune response and improve the efficacy of treatment, especially in the context of cancer immunotherapy.
- Focus on Global Access and Equity: Global access to mRNA vaccines is an important trend, with efforts being made to ensure equitable distribution of vaccines, especially in low- and middle-income countries. Companies are working to optimize mRNA production and distribution to reach underserved regions, which can further expand the market.
- Collaboration Between Pharma Giants: Pharmaceutical companies and biotech startups are increasingly collaborating to accelerate the development and commercialization of mRNA-based therapeutics. Partnerships between established players like Pfizer, Moderna, and BioNTech, and smaller biotech companies, are expected to drive innovation and market expansion.
Research Scope
The scope of research in the mRNA vaccines and therapeutics market spans various domains, including:
- Vaccine Development: Research is focused on mRNA vaccines for diseases beyond COVID-19, such as influenza, HIV, and malaria. There is also research into developing vaccines for cancer, using mRNA to instruct the immune system to target and destroy cancer cells.
- Therapeutic Applications: The use of mRNA technology in gene therapies for inherited diseases such as cystic fibrosis and Duchenne muscular dystrophy is a key area of research. Clinical trials are also being conducted on mRNA-based treatments for heart disease and autoimmune disorders.
- Immuno-oncology: Immunotherapy is one of the most promising areas for mRNA therapeutics. Research is focused on developing mRNA-based cancer vaccines and treatments that stimulate the body’s immune system to fight cancer more effectively.
- Delivery Systems: Efforts are being made to improve mRNA delivery technologies, with a focus on enhancing the stability and targeting of mRNA to specific cells. New delivery systems are being developed to overcome the challenges of efficient mRNA transport into cells.
Market Future Scope
The future of the mRNA vaccines and therapeutics market is highly promising, with several potential growth avenues:
- Expansion into Non-Viral Diseases: The future of mRNA technology is not limited to infectious diseases alone. It is expected to play a significant role in the treatment of chronic and non-viral diseases, particularly genetic disorders and cancers. Clinical trials for mRNA therapeutics aimed at addressing rare genetic diseases are expected to increase.
- Next-Generation mRNA Vaccines: The market will see the development of next-generation mRNA vaccines that are more effective and can address a broader range of diseases. These vaccines may offer long-lasting immunity with fewer side effects, paving the way for mRNA technology to become a mainstream tool for disease prevention.
- Wider Adoption in Cancer Therapy: mRNA-based cancer vaccines are expected to become an integral part of oncology treatments. With further research, mRNA vaccines could be personalized to target specific cancer mutations, offering new hope for cancer patients and creating a large potential market.
- Technological Advancements: With ongoing research in mRNA delivery systems and formulation improvements, the future will likely see more robust and scalable mRNA technologies. This will lower production costs and enable broader distribution and access.
- Global Health and Pandemic Preparedness: mRNA technology is seen as a key tool in responding to future pandemics. The platform’s ability to quickly adapt and produce vaccines for emerging diseases makes it an essential component of global health preparedness. Investment in mRNA technology is likely to increase as governments and organizations prepare for future outbreaks.
mRNA Vaccines and Therapeutics Market Developments
In September 2023, Moderna, a leading biotechnology company, expanded its mRNA-based medicine portfolio, achieving promising clinical results across cancer, rare diseases, and infectious diseases.
In January 2023, BioNTech SE, a global innovator in next-generation immunotherapy, signed a Memorandum of Understanding (MoU) with the Government of the United Kingdom to accelerate clinical trials for personalized mRNA immunotherapies. The collaboration aims to provide personalized cancer treatments to up to 10,000 patients by the end of 2030.
In December 2022, Moderna, Inc., a pioneer in messenger RNA (mRNA) vaccines and therapeutics, announced it received Emergency Use Authorization (EUA) from the US FDA for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, for children aged 6 months to 5 years.